Columnists
Tipsheet
Cartoons
Podcasts
Newsletters
Sections
Podcasts
Townhall TV
Election
Capitol Voices
Entertainment
Radio News
Live Blog
Topics
Sites
Hot Air
PJ Media
Bearing Arms
Twitchy
RedState
JOIN VIP
LOGIN
MY ACCOUNT
Account Settings
Newsletter Subscriptions
Log Out
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Alector Inc
(NQ:
ALEC
)
5.020
+0.100 (+2.03%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Nov 1, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
644,048
Open
5.000
Bid (Size)
4.700 (2)
Ask (Size)
5.200 (1)
Prev. Close
4.920
Today's Range
4.950 - 5.155
52wk Range
3.660 - 8.900
Shares Outstanding
83,351,778
Dividend Yield
N/A
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
Alector Presents Baseline Characteristics for Pivotal INFRONT-3 Phase 3 Clinical Trial at the 14th International Conference on Frontotemporal Dementias (ISFTD 2024)
September 19, 2024
From
Alector, Inc.
Via
GlobeNewswire
Alector to Participate in Upcoming Healthcare Conferences
August 29, 2024
From
Alector, Inc.
Via
GlobeNewswire
Performance
YTD
-37.17%
-37.17%
1 Month
+18.96%
+18.96%
3 Month
-0.79%
-0.79%
6 Month
-5.64%
-5.64%
1 Year
-14.63%
-14.63%
More News
Read More
Alector Reports Second Quarter 2024 Financial Results and Provides Business Update
August 07, 2024
From
Alector, Inc.
Via
GlobeNewswire
Alector to Host Mid-Year Earnings Conference Call
July 31, 2024
From
Alector, Inc.
Via
GlobeNewswire
Recap: Alector Q4 Earnings
February 27, 2024
Via
Benzinga
Earnings Scheduled For February 27, 2024
February 27, 2024
Via
Benzinga
Earnings Outlook For Alector
February 26, 2024
Via
Benzinga
Alector Presents Baseline Characteristics for INVOKE-2 Phase 2 Clinical Trial of AL002 at the Alzheimer's Association International Conference® 2024 (AAIC®)
July 28, 2024
From
Alector, Inc.
Via
GlobeNewswire
Alector to Present Data on Pipeline Focus Areas at the Alzheimer's Association International Conference® (AAIC®) 2024
July 23, 2024
From
Alector, Inc.
Via
GlobeNewswire
Alector to Participate in the H.C. Wainwright 5th Annual Neuro Perspectives Virtual Conference
June 20, 2024
From
Alector, Inc.
Via
GlobeNewswire
Perion Network Cuts Revenue Outlook, Joins Skye Bioscience And Other Big Stocks Moving Lower In Monday's Pre-Market Session
June 10, 2024
Via
Benzinga
Alector to Host Virtual Research and Development Event Highlighting Alector Brain Carrier Blood-Brain Barrier Technology Platform
June 10, 2024
From
Alector, Inc.
Via
GlobeNewswire
Alector to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference
June 03, 2024
From
Alector, Inc.
Via
GlobeNewswire
Alector to Participate in Upcoming Healthcare Conferences
May 09, 2024
From
Alector, Inc.
Via
GlobeNewswire
ALEC Stock Earnings: Alector Beats EPS, Beats Revenue for Q1 2024
May 08, 2024
Via
InvestorPlace
Alector Reports First Quarter 2024 Financial Results and Provides Business Update
May 08, 2024
From
Alector, Inc.
Via
GlobeNewswire
Race To Treat Alzheimer's Disease Is Heating Up Despite Eli Lilly's Setback
March 28, 2024
Via
Investor's Business Daily
Exposures
Product Safety
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday
March 06, 2024
Via
InvestorPlace
Alector to Participate in Upcoming Healthcare Conferences
February 28, 2024
From
Alector, Inc.
Via
GlobeNewswire
Alector Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
February 27, 2024
From
Alector, Inc.
Via
GlobeNewswire
Alector to Host Fourth Quarter and Full-Year 2023 Earnings Call
February 20, 2024
From
Alector, Inc.
Via
GlobeNewswire
Alector Announces First Patient Dosed in PROGRESS-AD Phase 2 Clinical Trial of AL101/GSK4527226 in Patients with Early Alzheimer’s Disease
February 08, 2024
From
Alector, Inc.
Via
GlobeNewswire
FDA Grants Latozinemab Breakthrough Therapy Designation for Frontotemporal Dementia Due to a Progranulin Gene Mutation (FTD-GRN)
February 07, 2024
From
Alector, Inc.
Via
GlobeNewswire
Brain Disease Cures: 3 Neuroscience Stocks Targeting Revolutionary Breakthroughs
January 23, 2024
Via
InvestorPlace
Alector Announces Closing of Public Offering
January 19, 2024
From
Alector, Inc.
Via
GlobeNewswire
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.